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Summary In 73 CAP-1 treated stage III and IV ovarian cancers. the prognostic significance of morpho-
metric features and cellular DNA content has been evaluated in comparison with histologic type, grade of
differentiation and a number of clinical characteristics. Borderline tumours were excluded from the study.
Median follow-up was 44 months, median survival time 36 months. Single features associated with prognosis
were (in order of decreasing significance according to single variate analysis): FIGO stage (P=0.0002). bulky
disease (P=0.004), standard deviation and mean of nuclear area (P=0.0006 and P=0.01). cellular DNA
content (P=0.01). mitotic activity index (P=0.08) and volume percentage epithelium (P=0.13. not quite
significant). Tumours with a mean nuclear area >70,um2 (which occurred in 35% of the cases) were nearly
all aneuploid. Multivariate analysis showed that the statistically most significant prognostic combination of
features consisted of mean nuclear area, presence or absence of bulky disease and FIGO stage (in order of
decreasing importance) (Mantel-Cox=23.07. P<0.00001). A low value for the multivariate function of this
combination of features was associated with a poor prognosis within 24 months. a high value with a
favourable outcome. Another favourable combination of features appeared to be diploid cellular DNA
content and a low mitotic activity index (11 patients. one died). However. even with the prognostically most
favourable combination of these features, several patients died. Of all combinations of features investigated.
only two were associated with an excellent prognosis (low mitotic activity index and low volume percentage
epithelium). Cancers of 7 patients (10%) displayed such features. and none of them died during the follow-up
period (minimally 20 and maximally 54 months). It is concluded that morphometric and flow cytometric
analysis can provide significant and objective information to predict the prognosis of cis-platin-treated
advanced ovarian cancer patients.
A significant increase in response rate. median and long-time
survival has been reported during recent years for patients
with stage III and IV advanced ovarian carcinoma as a
result of debulking surgery and cis-platin containing
combination chemotherapy (Piver. 1984: Neijt et al., 1984;
Wils et al., 1986). However, in spite of such treatment, the
majority of patients still die from disease within a few years
of diagnosis. Because cis-platin based chemotherapy has
considerable side-effects, prognostic indicators are of major
interest. Several features are associated with prognosis, and
tumour burden before the initiation of chemotherapy at
present is regarded as the most important factor predicting
the clinical outcome which stresses the need for cytoreductive
surgery. Indeed, optimally debulked patients do better than
those in whom this procedure is impossible or have
inadequate tumour removal. Extent of disease is another
factor. and stage III patients have a significantly better
survival than those in stage IV. However, even in patients
with relatively favourable signs, some still die from recurrent
cancer. Thus, it is important to consider other prognostic
factors as well.
Quantitative cell and tissue features of ovarian tumours
have been proven to be prognostically important. In
borderline tumours, certain morphometric characteristics
such as mitotic activity index (MAI) and volume percentage
epithelium (VPE) exceeded the prognostic value of histologic
type. nuclear and histologic grade and even that of extent of
disease (Baak et al., 1985). A combination of high values of
MAI and VPE were associated with a very poor outcome,
and the same phenomenon was found in stage I cancers.
This finding was especially important because the number of
borderline or stage I cancer patients with an unfavourable
outcome is small, and as a consequence, techniques to detect
such small subsets of unfavourable patients should have a
high predictive value.
Other quantitative features such as nuclear size and
cellular DNA content also have prognostic value both in
early (Erhardt et al., 1984; Baak et al., 1986,1987) and
late ovarian cancers Hedley et al., 1985). However, in spite of
the significance of these findings, a method which can
identify advanced disease patients with an excellent prog-
nosis remains to be developed.
In the present study, we have ascertained whether the
above quantitative features have prognostic value in
advanced ovarian cancer patients, and whether they provide
independent prognostic information in addition to well
established cnrteria such as stage and tumour burden.
Materials and methods
Patient selection
Patients and material were obtained from a previous study
(Wils et al., 1986). Patients were entered in this study
between June 1980 and December 1984. Briefly, eligibility
criteria included: age (below or equal to 70 years); histologic
proof of epithelial ovarian carcinoma (borderline tumours
were excluded); stage III-IV disease; no previous chemo-
therapy or radiotherapy and adequate bone marrow, renal,
and hepatic function.
Patients were classified during surgery as having bulky
disease (at least one metastatic lesion > 5 cm in diameter) or
non-bulky disease (Gnrffiths et al., 1979; Wharton & Herson,
1981). Tumour debulking was accomplished to the maximum
extent deemed safe by the surgeon. Optimal debulking was
defined as having no residual tumour or limited residual
tumour (nodules equal to or smaller than 1.5cm).
Chemotherapy consisted of a combination of cis-platin
50mgm-2 with adequate pre- and posthydration,
doxorubicin. 50 mgm-2 and cyclophosphamide 500mg m - 2,
i.v. on day 1 at 28-day intervals (CAP-I).
Assessment of response was classified as complete (CCR),
partial (PR), progressive disease (PD) or stable disease (SD)
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(anything between PR and PD). Further analysis showed a
strong correlation between the different types of responses,
and therefore, survival-or-not was used as the (most
objective) criterion. Quantile (75th) and median (50th)
survival of all patients were at 17 and 36 months. At 58
months, 44% of the patients were still alive.
Pathological review
All tissues were routinely processed (at least 10 tissue
sections of any tumour or one tissue block for each cm of
diam., whichever is greater, in agreement with others,
Kempson, 1976). Standard 5pm H&E stained, paraffin
sections were used. Tumours were classified as serous,
mucinous or endometrioid cystadenocarcinoma, clear-cell
carcinoma or undifferentiated adenocarcinoma.
Grading was performed according to the following pre-
defined criteria:
- Well differentiated:
Nuclear atypia and/or multilayering more than 3 and/or
invasive growth, but no features mentioned below.
- Moderately differentiated:
Any of the signs of malignancy mentioned above but with
cribriform growth pattern of at least 450 jm diam.
( =diam. of the 40 x objective used, which had a
numerical aperture of 0.75). A cribriform growth pattern is
defined as more than one round lumen in an epithelial
field, without intervening stroma.
- Poorly differentiated:
Any of the above-mentioned characteristics of malignancy,
but in the presence of solid epithelial areas (size at least
450 jm diam.) or multinucleated giant cells.
The poorest degree of differentiation (highest grade)
available determined the overall grade of the tumour. In this
way, 12 of the tumours were classified as well (9 survivors),
12 as moderately (7 survivors) and 49 as poorly
differentiated (25 survivors). Borderline tumours (no invasive
growth, multilayering <3; no marked nuclear atypia) were
carefully excluded.
Morphometry
Morphometric analysis was performed in the most atypical
areas of the tumour. Details of the morphometric techniques
utilized have been described in detail elsewhere (Baak et al.,
1981, 1985). The areas in which the measurements were
performed were carefully selected on the basis of the
following criteria: (a) highest cellularity, (b) highest mitotic
rate, (c) strongest atypicality, (d) avoidance of areas with
inflammation, necrosis, or calcification (if present). If both
material from primary and metastatic tumour tissue was
available, the former was chosen for the measurements.
Selection of the areas for measurement appeared reproduc-
ible between different technicians after careful instruction.
Measurements in randomly selected areas in the sections did
not produce significant results for the prediction of the
outcome.
In these selected areas, randomly selected epithelial cell
nuclei with intact nuclear membrane and chromatin were
measured at a magnification of x 2,000 and the area,
perimeter, shape factor (4 X area/squared perimeter), longest
axis, shortest axis, and nuclear axes ratio were assessed. The
mean and standard deviations of these features were calcu-
lated. Nuclear measurements were carried out on a
commerically available graphic tablet coupled with a
microcomputer (Mop-Videoplan, Kontron, Munich, FRG
software version 5.42). The number of nuclei measured was
determined as follows: With the magnification used, inter-
and intraobserver coefficient of variation of the above-
mentioned features measured in the same nucleus was
- 1%.
Usually, 15-20 nuclei was sufficient, but to be on the safe
side at least 50 nuclei were measured in each case.
The percentages of epithelial and stromal tissue were
measured by a point counting technique (Weibel, 1979) using
a 42-point grid (9.2x7.6cm) placed on a projection micro-
scope at a magnification of 200 x. At least 320 points were
counted in each case (3.5mm2 at specimen level).
The number of mitotic figures was assessed in 25 fields
(mitotic activity index=MAI) at a magnification of 400x
(planapo objective x 40, numerical aperture 0.75), the diam.
of each field being 450pm. Counts were performed in the
most cellular areas as mentioned above, in contiguous fields,
but only if those fields contained t;50% epithelial tissue.
Recovery tests of all measurements showed a coefficient of
variation of 3-7% for the means of nuclear features, the
percentages of epithelial and stromal tissue, and the MAI,
both within and between different instructed observers.
In earlier publications on borderline tumours and stage I
cancers of the ovary, three categories of a combination of
morphometric features mitotic activity index (MAI) and
volume percentage epithelium turned out to be especially
prognostically significant. Therefore, these combinations
have been discerned in this study as well, and were evaluated
in addition to the analysis of single and other combinations
of features:
- Category A: MAI below 30, volume percentage epithelium
below 65
- Category B: MAI below 30, volume percentage epithelium
equal to or above 65
- Category C: MAI equal to or above 30.
In previous studies, these categories had the strongest prog-
nostic value of many other subsets of features evaluated,
exceeding the prognostic significance of subjective grading
(Baak et al., 1985, 1986, 1987). In the present study, there
were 7 patients (11% of the total group) categorized as A
(none died), 14 as B (6 died) and 52 as C (26 died).
Flow cytometry
The flow cytometric method used was similar as described in
detail elsewhere (Hedley et al., 1983). The tissue blocks from
which the histological slides had been cut for qualitative and
quantitative microscopy were selected. Alternating 4,jm and
50jm thick sections were made. The 4jm sections were
stained with H&E, and used to control the content of the
50jm sections ('sandwich technique'). At least two 50pm
thick sections were cut, placed in 10ml centrifuge tubes and
dewaxed in 6ml xylene for 15min at room temperature.
Rehydration was performed by immersion in 100%, 95%,
70% and 50% ethanol with centrifugation and decantation
of the supernatant after each step.
The material was then washed in PBS (pH=7) and treated
with 2.5ml 0.05% protease (Sigma chemical company, Saint
Louis, USA: nr. P-4789 10Umg-1, type 7). In between,
frequent vortex mixing was applied. After 30min incubation
at 37°C, the cells were washed and filtrated through a 50pm
nylon gauze. The cells then were stained with at least
1 jgml-' 4', 6-diaminido-2-phenyl-indole dihydrochloride
(DAPI, Sigma nr. D-1388, 100mg). No RNase pre-treatment
was applied. The PAS TT flow cytometer (Partec, Arlesheim,
Switzerland) was used for the analysis, which was done
within 3h after preparation of the specimens. In agreement
with usual statistics, the coefficient of variation (CV) was
defined as the ratio of the half width at 61% height (2 x
standard deviation) of the GO/G1 peak to the value of the
GO/G1 peak on the abscissa. Fixed lymphocytes served as an
external standard for instrument setting (optimal CV 1.5%,
mean value 2.1%). The median CV of the ovarian specimens
was 4.8, mean 5.0, s.d. 1.53, range 2.2-8.6. In older tissue
blocks (> 10 years old) the histograms were sometimes
inadequate, and therefore had to be discarded (which
occurred in 9 tumours or 12% of all the cases, in agreement
with Zimmerman et al., 1987). In all those cases, repeated
measurements on new preparations always gave the same
inadequate results.MORPHOMETRY AND DNA CONTENT IN LATE OVARIAN CANCERS 505
The first modal cell peak was regarded as the diploid
peak. If in addition to the diploid (Go/G1) and G2/M peak
one or more additional peaks were detected, the tumour was
classified as aneuploid. Special attention was paid to the
group of diploid tumours with a coefficient of variation
exceeding 5.5%, which initially were regarded as 'pseudo-
diploid', because near-diploid aneuploid tumours could
masquerade as diploid with a 5.5<CV<8.6. It transpired
that the prognosis of patients with such a tumour
(CV>5.5%) was the same as that of patients with a diploid
tumour and a CV<5.5%. Further survival analysis showed
that there were also no differences between diploid tumours
with a CV<4.5%, 4.5%<CV<5.5% and CV>5.5%
(Mantel-Cox, P=0.70). These results do not support the
hypothesis that the CV of diploid tumours is of prognostic
significance in cis-platin-treated ovarian tumour patients and
therefore these tumours were grouped together as diploid.
Tumours in which the 4c+5% (1.9<DNA index <2.1)
peak was greater than 10% of the diploid peak and also had
a clear tail at the right of that peak with a second G2M peak
at a double distance were classified as peritetraploid. On
these terms, there were 25 diploid tumours, 9 were peri-
tetraploid and the other 30 were aneuploid.
Repeated measurements of the same blocks, and different
tissue blocks from the same patients, showed that assessment
of DNA-index was highly reproducible (r>0.97).
Statistical methods
Survival (Kaplan-Meier) curves were analyzed for each
feature separately using the Mantel-Cox statistic. Quanti-
tative nuclear features were delineated for this analysis in
three categories of approximately the same size. Secondly, a
multivariate survival analysis was performed on the 64 cases
in which all features (including cellular DNA content) were
known, using Cox's regression model (also called propor-
tional hazards model). These survival analyses take into
account the time at risk from operation to either death or
last follow-up. All analyses were done with the BMDP
package, using the programs life tables, survival analysis
with covariates, and stepwise, logistic regression analysis,
respectively (Dixon et al., 1981).
Results
Single variant analysis
A summary of features which we found significantly
associated with survival is shown in Table I. FIGO stage
appeared to be the strongest single prognostic factor, but a
number of FIGO III patients died from recurrent disease.
Bulky disease is another important prognostic factor,
however, of the 18 patients without bulky disease three
developed recurrent disease. All patients without bulky
disease were in FIGO stage III.
Mean and standard deviation of nuclear area showed a
significant correlation with prognosis. A value below
56.3pim2 is associated with a better outcome. However there
is not a unique cut-off point of these features to identify
patients with an excellent prognosis: also some patients with
small nuclei died rapidly after diagnosis. The same is true for
the standard deviation of nuclear area.
By flow cytometry, 25 cases were diploid, 9 peritetraploid
and 30 aneuploid. DNA index was significantly correlated
with prognosis, as 18 (72%) of the 25 patients with diploid
tumours survived, 17 (57%) of the 30 aneuploid and only
one (11%) of the 9 with peritetraploid tumour (Mantel-
Cox=8.61, P=0.01). The difference in survival between
patients with a peritetraploid and aneuploid tumour is
significant as well (Mantel-Cox =5.78, P=0.02). Further
division of the diploid tumours according to the coefficient
of variation (CV) of the diploid peak (CV<4.5%, 4.5%
<CV<5.6% and CV_5.6%) did not give additional
prognostic information.
Special attention was paid to the correlation of cellular
DNA content with morphometric features. Especially
striking was it's correlation with mean nuclear area
(Spearman test: 0.32, see Figure 1). If mean nuclear area
exceeded 69.1 ym2, nearly all tumours were aneuploid.
Multivariate analysis
A number of combinations of the above-mentioned features
have been studied. Only the most promising ones will be
shown here. Combination of FIGO stage and bulkiness of
disease resulted in three groups of patients, with a
favourable (FIGO III and non-bulky disease, n= 18),
intermediate (FIGO III and bulky disease, n=39) and poor
prognosis (FIGO IV, which all had bulky disease, n= 16).
(Mantel-Cox 17.5; P=0.0002). However, even in the
relatively small favourable group, 3 of the 18 women died
shortly after the initial diagnosis (see Figure 2).
Cox regression analysis pointed to mean nuclear area as
the strongest prognostic factor, followed by FIGO stage and
presence or absence of bulky disease. The resulting
Advanced Carcinoma of the Ovary Prognostic Score
(ACOPS) is as follows:
ACOPS=2.8250-0.04070 * mean nuclear area
(in im2, with one decimal)
-0.67367 * FIGO (111=3, IV=4)
-0.60381 * bulky disease (1 =no, 2=yes)
Where ACOPS
>-2.520 means favourable
<- 3.255 means unfavourable
in between intermediate prognosis
(n=24, 19 survived)
(n=24, 6 survived)
(n=25, 16 survived)
Although this combination of morphometric features and
extent of disease features failed to identify a subgroup of
patients with an excellent prognosis, it allowed character-
ization of patients with an unfavourable prognosis (Figure
3). The results were highly significant (Mantel-Cox=23.07;
P<0.00001).
In 25 patients with diploid tumours simultaneous
consideration with mitotic activity index is prognostically
important. If MAI<30, only one of the 11 patients died
(within 10 months after the initial diagnosis), in contrast to 6
of 14 in which MAI was >30. The latter 6 patients all died
within 22 months. However, this result is not quite signifi-
cant (P=0.08).
Using the same combinations of mitotic activity index
(MAI) and volume % epithelium (VEPI) as described before
(category A =MAI<30, VEPI <65; category B =MAI<30,
VEPI >65, and category C =MAI>30), all 7 category A
patients survived, 8 of 14 category B and 26 of 52 category
C patients. Analysis of category A versus B and C together
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Ovarian cancers
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<563 >=563<691 >=691
Mean nuclear area
Figure 1 Correlation between cellular DNA and mean nuclear
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Table I Single features analyzed and their independent prognostic significance
Median
survival
Feature n Alive time (months) Mantel-Cox P
FIGO III
IV
Bulky no
yes
S.d. nuclear area
< 14.3
14.3-20.8
>20.8
Mean nuclear area
<56.3
56.3-69.1
>69.1
DNA index
diploid
peritetraploid
aneuploid
DNA index
diploid
aneuploid+peritetraploid
Mitotic activity index
.30
>30
Volume % epithelium
.74
74-86
>86
Volume % epithelium
<65
>65
Age
.45
>45
Grade
well
moderately
poor
CV diploid tumours
<4.5
4.5 <CV< 5.5
.5.5
57
16
37
14
44
14
18 15 not reached
55 26 23
24
25
24
24
25
24
25
9
30
17
16
8
17
15
9
18
1
17
not reached
45
18
not reached
45
20
not reached
19
42
25 18 not reached
39 18 36
21 15 not reached
52 26 21
24
25
24
17
10
14
not reached
21
44
11 9 not reached
62 32 26
13 10 not reached
60 31 35
12
12
49
8
8
9
9
7
25
S
6
7
not reached
40
24
33
not reached
not reached
Ovarian cancers FIGO III + IV
Months
Figure 2 Kaplan-Meier survival curves of patients with FIGO
III with and without bulky disease and FIGO IV. *, FIGO III
non-bulky (n= 18); 0, FIGO III bulky (n=39); +, FIGO IV
(n= 16).
Ovarian cancers FIGO III + IV
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Figure 3 Survival curves according to the strongest combination
of features (FIGO stage, bulky disease or not, and mean nuclear
area). *ACOPS>-2.520 (n=24); 0 ACOPS> -3.255<-2.520
(n =25); tACOPS< -3.255 (n =24).
was significant (Figure 4, Mantel-Cox=4.95, P= 0.03). Two
of the seven category A patients had FIGO IV disease (both
alive and well at 27 and 39 months). It is important to note
that the presence of category A morphometric features was
13.79
8.30
14.94
9.10
8.6
4.2
2.89
5.02
2.25
1.19
2.63
0.73
0.0002
0.004
0.0006
0.01
0.01
0.05
0.08
0.08
(0.13)
0.27
0.27
0.70
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Figure 4 Survival curves of patients with a mitotic activity
index <30 and volume % epithelium <65 (n=7) versus patients
in which any of these two features is equal to or above these
thresholds (n =66). *, Morphometric category A (n =7); O,
morphometric category B and C (n =66).
the only combination of all single and combined features
analyzed which allowed identification of patients with an
excellent prognosis. Follow-up time of category A patients is
minimally 20 and maximally 54 months. Combination of
these morphometric categories with DNA index did not
result in improved accuracy of prognosis prediction.
Discussion
It is essential in prognostic studies to investigate uniformly
treated patients. To our knowledge, the present investigation
is the first in which morphometric and flow cytometric
analyses have been performed, in which this condition has
been met. Furthermore, it is important that only invasive
cancers have been studied (excluding borderline tumours).
It would be of obvious benefit to patients with advanced
ovarian cancer to have accurate tests to predict their
prognosis. Such prognostic tests should be reliable, quick to
apply, simple and generally applicable.
The present results suggest that quantitative cell and tissue
features of the tumour fulfil these demands to a large extent.
None of the 7 patients with a low MAI (<30) and low VPE
(<65) has died so far (with minimum follow-up of 20 and
maximally 54 months). Two of these seven patients had
stage IV disease, (one with pulmonary manifestations), and
borderline tumours were carefully excluded.
As borderline tumours probably never spread beyond the
peritoneal cavity, these facts indicate that the small
proportion of stage IV cancers with a good prognosis can be
identified by morphometry, at least partially. It is important
that in a previous study of borderline tumours, and another
investigation of FIGO I invasive cancers the same criteria
also selected patients with an excellent prognosis. The per-
centage of patients with these favourable morphometric
features decreases from borderline (84.2%) to FIGO I
(11/32=34.4%) and FIGO III and IV patients (7/73=9.6%),
but in these tumours of different grades and stages, the
presence of these morphometric features is associated with
an excellent prognosis. This suggests that they reflect a basic
biological process of the tumour associated with relatively
non-malignant behaviour. Apparently, this process is
common to a wide range of tumours, such as borderline
tumours and stage I-IV ovarian cancers. Whereas in
untreated borderline tumours the presence of the morpho-
metric characteristics is associated with lack of distant
metastases, the same features in FIGO III/IV cancers
indicate a high likelihood of success of chemotherapy. The
question could be raised, whether stage III and IV patients
with category A tumours should be left untreated; the final
answer requires large scale studies. Cellular DNA content
was prognostically significant in two studies (Erhardt et al.,
1984; Hedley et al., 1985) although this was not confirmed in
another (Rutgers et al., 1988). In the present material,
diploid tumours did better than aneuploid ones, but the
difference was not as emphatic as in Friedlander's (1984)
original study. In FIGO IV cancers, DNA content was of no
value, which is in agreement with the more recent data of
Hedley et al. (1985). Perhaps the discrepancy concerning the
prognostic value of cellular DNA content is caused by
different proportions of stage III and IV patients in the
studies mentioned. Whatever the reason, it is interesting that
DNA index is strongly associated with mean nuclear area.
Both features are prognostically important. With multi-
variate analysis the value of mean nuclear area exceeded that
of stage and bulky disease, but combination of these three
features in the ACOPS-rule was prognostically the most
significant. It has to be admitted that assessment of nuclear
area requires specialized equipment and is somewhat more
time-consuming than determination of the morphometric
features MAI and VPE. Moreover, the latter two features
were more sensitive for the identification of patients with a
very good reaction on cis-platin-based treatment. Thus,
sequential analysis of first MAI and VEPI, and secondly the
ACOPS-rule seems practical. If MAI and VEPI are low, (as
indicated above), prognosis of patients treated with cis-
platin-containing regimens probably will be successful,
especially also if the tumour is diploid by DNA flow
cytometry. If MAI and/or VEPI are high, a low value of
ACOPS-rule (.3.160) indicates a very low success rate
(< 10%) and more than 90% of the patients will die within 2
years. The majority of these patients will not be debulkable,
and therefore are candidates for new investigational
approaches or for single agent treatment. In the few cases
that are debulkable, more aggressive chemotherapy such as
intraperitoneal, eventually combined with intravenous
administration should be considered.
Although nuclear size is an important predictor of the
sensitivity of tumour cells to cis-platin treatment, it is not
quite clear which underlying cell-biological mechanism it
reflects. Nuclear size is probably strongly related to the
dynamic nuclear protein matrix (Diamond et al., 1982). This
three-dimensional protein skeleton of the nucleus may have
an important regulatory role in the nucleus, because it has
been found to be the site of androgen binding to the prostate
cell nucleus (Barrack & Coffey, 1980), and it has been shown
that the matrix possesses fixed sites for deoxyribonucleic acid
synthesis (Pardoll et al., 1980). It is thus understandable that
changes in nuclear size might correspond to certain funda-
mental biological phenomena affecting tumour properties
associated with malignancy. Whatever the mechanism is,
nuclear area is a simple and rapidly measurable feature
which can give an impression about complicated interactions
of cis-platin, and perhaps also other drugs on the one hand,
and biological processes at the cellular level on the other.
As mean and standard deviation of nuclear area are
strongly correlated, by multivariate analysis only the mean
area was selected. However, it is important to realize what
the biological consequence of the significance of the poor
prognostic value of high standard deviation is. It means that
a certain clone of cells with much larger nuclei exists within
the total population of tumour cells, and that these cells are
responsible to a large extent for the insensitivity to cis-platin
treatment.
Indeed, in biopsies of non-responders taken at second or
third look operation, tumour cells with large nuclei often
prevail. Studies on therapeutic response modifiers therefore
should concentrate on these cells. Fortunately, in principle it
is possible to isolate these cells from tumours by cell sorting.
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However, it should be admitted that 6 of the 24 patients in
which the tumours had low standard deviations have died as
well. There are two explanations for this. First, it may be
that due to sampling errors, areas with large nuclei having
been missed. The other possibility is that certain tumours
are insensitive to cis-platin, in spite ofthe fact that they contain
small nuclei. If this is the case, one would expect that cis-
platin treatment is of little use in borderline tumours and
well differentiated cancers. As far as we know, there is
presently no proof for or against this hypothesis. As
mentioned, in the present study only invasive cancers were
used, and borderline tumours were carefully excluded.
In conclusion, morphometric and flow cytometric analyses
can provide significant and objective information to predict
the prognosis of advanced ovarian cancer patients treated
with cis-platin. The results described indicate that the same
features have prognostic value in stage III and IV cancers as
described in previous studies for borderline tumours and
stage I invasive cancers. This suggests that a common basic
tumour biological process is involved and also that the
quantitative features express this process with a high degree
of accuracy. It is an advantage that the quantitative methods
used are objective and reproducible. Nevertheless, a criticism
could be that it has been carried out retrospectively on one
set of patients. It remains to be determined whether the same
results will be obtained in another retrospective study or,
preferably, in a prospective investigation. Furthermore, the
value of the score might change with different dosages or
chemotherapy regimens. Therefore, we are now performing
these investigations prospectively in newly treated patients. A
second criticism could be that an expert pathologist or
experienced technician is required to select the worst areas
for measurements. Repeated measurements are highly repro-
ducible however, also after blind re-selection of essential
areas by other experts. Furthermore, automatic recognition
of the most cellular areas in the epithelium is in an advanced
stage of development (Schipper et al., 1987) and full
automation of morphometric assessment can be expected
within 2 to 4 years.
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